Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Parkinson's Disease

  Free Subscription


Articles published in Exp Neurol

Retrieve available abstracts of 45 articles:
HTML format
Text format



Single Articles


    September 2018
  1. COOPER JF, Spielbauer KK, Senchuk MM, Nadarajan S, et al
    alpha-synuclein expression from a single copy transgene increases sensitivity to stress and accelerates neuronal loss in genetic models of Parkinson's disease.
    Exp Neurol. 2018 Sep 5. pii: S0014-4886(18)30432.
    PubMed     Text format     Abstract available


    August 2018
  2. OLIVEIRA LM, Falquetto B, Moreira TS, Takakura AC, et al
    Orexinergic neurons are involved in the chemosensory control of breathing during the dark phase in a Parkinson's disease model.
    Exp Neurol. 2018;309:107-118.
    PubMed     Text format     Abstract available


  3. CHENG S, Tereshchenko J, Zimmer V, Vachey G, et al
    Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector.
    Exp Neurol. 2018;309:79-90.
    PubMed     Text format     Abstract available


  4. WU S, Lei L, Song Y, Liu M, et al
    Mutation of hop-1 and pink-1 attenuates vulnerability of neurotoxicity in C. elegans: the role of mitochondria-associated membrane proteins in Parkinsonism.
    Exp Neurol. 2018;309:67-78.
    PubMed     Text format     Abstract available


    July 2018
  5. HOSSAIN MM, Weig B, Reuhl K, Gearing M, et al
    The anti-parkinsonian drug zonisamide reduces neuroinflammation: Role of microglial Nav 1.6.
    Exp Neurol. 2018;308:111-119.
    PubMed     Text format     Abstract available


    June 2018
  6. ZHANG Z, Shen Y, Luo H, Zhang F, et al
    MANF protects dopamine neurons and locomotion defects from a human alpha-synuclein induced Parkinson's disease model in C. elegans by regulating ER stress and autophagy pathways.
    Exp Neurol. 2018 Jun 27. pii: S0014-4886(18)30206.
    PubMed     Text format     Abstract available


    May 2018
  7. DU TT, Chen YC, Lu YQ, Meng FG, et al
    Subthalamic nucleus deep brain stimulation protects neurons by activating autophagy via PP2A inactivation in a rat model of Parkinson's disease.
    Exp Neurol. 2018 May 21. pii: S0014-4886(18)30127.
    PubMed     Text format     Abstract available


    April 2018
  8. EKIMOVA IV, Plaksina DV, Pastukhov YF, Lapshina KV, et al
    New HSF1 inducer as a therapeutic agent in a rodent model of Parkinson's disease.
    Exp Neurol. 2018 Apr 25. pii: S0014-4886(18)30099.
    PubMed     Text format     Abstract available


    March 2018
  9. ROUILLARD C, Baillargeon J, Paquet B, St-Hilaire M, et al
    Genetic disruption of the nuclear receptor Nur77 (Nr4a1) in rat reduces dopamine cell loss and l-Dopa-induced dyskinesia in experimental Parkinson's disease.
    Exp Neurol. 2018 Mar 9. pii: S0014-4886(18)30070.
    PubMed     Text format     Abstract available


    February 2018
  10. SUN X, Aime P, Dai D, Ramalingam N, et al
    Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease.
    Exp Neurol. 2018 Feb 9. pii: S0014-4886(18)30022.
    PubMed     Text format     Abstract available


    January 2018
  11. REN M, Guo Y, Wei X, Yan S, et al
    TREM2 overexpression attenuates neuroinflammation and protects dopaminergic neurons in experimental models of Parkinson's disease.
    Exp Neurol. 2018;302:205-213.
    PubMed     Text format     Abstract available


  12. YU Q, Huang Q, Du X, Xu S, et al
    Early activation of Egr-1 promotes neuroinflammation and dopaminergic neurodegeneration in an experimental model of Parkinson's disease.
    Exp Neurol. 2018 Jan 11. pii: S0014-4886(18)30016.
    PubMed     Text format     Abstract available


  13. LIMA JC, Oliveira LM, Botelho MT, Moreira TS, et al
    The involvement of the pathway connecting the substantia nigra, the periaqueductal gray matter and the retrotrapezoid nucleus in breathing control in a rat model of Parkinson's disease.
    Exp Neurol. 2018 Jan 3. pii: S0014-4886(18)30003.
    PubMed     Text format     Abstract available


    December 2017
  14. GALATI S, Song W, Orban G, Luft AR, et al
    Cortical slow wave activity correlates with striatal synaptic strength in normal but not in Parkinsonian rats.
    Exp Neurol. 2017;301.
    PubMed     Text format     Abstract available


  15. CENCI MA, Olanow CW
    Translating scientific advances into disease-modifying therapies for Parkinson's Disease.
    Exp Neurol. 2017;298.
    PubMed     Text format    


  16. BRUNDIN P, Dave KD, Kordower JH
    Therapeutic approaches to target alpha-synuclein pathology.
    Exp Neurol. 2017;298.
    PubMed     Text format     Abstract available


  17. SMITH L, Mullin S, Schapira AHV
    Insights into the structural biology of Gaucher disease.
    Exp Neurol. 2017;298.
    PubMed     Text format     Abstract available


  18. OLANOW CW, Kieburtz K, Katz R
    Clinical approaches to the development of a neuroprotective therapy for PD.
    Exp Neurol. 2017;298.
    PubMed     Text format     Abstract available


    November 2017
  19. BONATO JM, Bassani TB, Milani H, Vital MA, et al
    Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson's disease in rats.
    Exp Neurol. 2017 Nov 18. pii: S0014-4886(17)30323.
    PubMed     Text format     Abstract available


  20. HARMS AS, Thome AD, Yan Z, Schonhoff AM, et al
    Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease.
    Exp Neurol. 2017;300:179-187.
    PubMed     Text format     Abstract available


  21. WANG YY, Wang Y, Jiang HF, Liu JH, et al
    Impaired glutamatergic projection from the motor cortex to the subthalamic nucleus in 6-hydroxydopamine-lesioned hemi-parkinsonian rats.
    Exp Neurol. 2017;300:135-148.
    PubMed     Text format     Abstract available


  22. CHAO H, Liu Y, Fu X, Xu X, et al
    Lowered iPLA2gamma activity causes increased mitochondrial lipid peroxidation and mitochondrial dysfunction in a rotenone-induced model of Parkinson's disease.
    Exp Neurol. 2017 Nov 2. pii: S0014-4886(17)30291.
    PubMed     Text format     Abstract available


    October 2017
  23. FRANCARDO V, Schmitz Y, Sulzer D, Angela Cenci M, et al
    Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease.
    Exp Neurol. 2017 Oct 5. pii: S0014-4886(17)30243.
    PubMed     Text format     Abstract available


  24. BLESA J, Trigo-Damas I, Dileone M, Del Rey NL, et al
    Compensatory mechanisms in Parkinson's disease: Circuits adaptations and role in disease modification.
    Exp Neurol. 2017 Oct 4. pii: S0014-4886(17)30244.
    PubMed     Text format     Abstract available


    September 2017
  25. KUHN J, Haumesser JK, Beck MH, Altschuler J, et al
    Differential effects of levodopa and apomorphine on neuronal population oscillations in the cortico-basal ganglia loop circuit in vivo in experimental parkinsonism.
    Exp Neurol. 2017 Sep 8. pii: S0014-4886(17)30235.
    PubMed     Text format     Abstract available


    August 2017
  26. JAMES SURMEIER D, Halliday GM, Simuni T
    Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease.
    Exp Neurol. 2017 Aug 2. pii: S0014-4886(17)30206.
    PubMed     Text format     Abstract available


    July 2017
  27. WEST AB
    Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease.
    Exp Neurol. 2017 Jul 29. pii: S0014-4886(17)30203.
    PubMed     Text format     Abstract available


  28. KO WKD, Bezard E
    Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to alpha-synuclein targeted disease modification.
    Exp Neurol. 2017 Jul 29. pii: S0014-4886(17)30202.
    PubMed     Text format     Abstract available


  29. FISCHER P, Pogosyan A, Cheeran B, Green AL, et al
    Subthalamic nucleus beta and gamma activity is modulated depending on the level of imagined grip force.
    Exp Neurol. 2017;293:53-61.
    PubMed     Text format     Abstract available


    June 2017
  30. CROTTY GF, Ascherio A, Schwarzschild MA
    Targeting urate to reduce oxidative stress in Parkinson disease.
    Exp Neurol. 2017 Jun 13. pii: S0014-4886(17)30157.
    PubMed     Text format     Abstract available


  31. MEADOWS SM, Chambers NE, Conti MM, Bossert SC, et al
    Characterizing the differential roles of striatal 5-HT1A auto- and hetero-receptors in the reduction of l-DOPA-induced dyskinesia.
    Exp Neurol. 2017;292:168-178.
    PubMed     Text format     Abstract available


    May 2017
  32. MOREIRA S, Fonseca I, Nunes MJ, Rosa A, et al
    Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson's disease.
    Exp Neurol. 2017 May 25. pii: S0014-4886(17)30126.
    PubMed     Text format     Abstract available


  33. LAZARO DF, Pavlou MAS, Outeiro TF
    Cellular models as tools for the study of the role of alpha-synuclein in Parkinson's disease.
    Exp Neurol. 2017 May 16. pii: S0014-4886(17)30124.
    PubMed     Text format     Abstract available


    April 2017
  34. SCOTT L, Dawson VL, Dawson TM
    Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes.
    Exp Neurol. 2017 Apr 23. pii: S0014-4886(17)30102.
    PubMed     Text format     Abstract available


  35. ALAM M, Rumpel R, Jin X, von Wrangel C, et al
    Altered somatosensory cortex neuronal activity in a rat model of Parkinson's disease and levodopa-induced dyskinesias.
    Exp Neurol. 2017 Apr 23. pii: S0014-4886(17)30101.
    PubMed     Text format     Abstract available


  36. OLIVEIRA LM, Tuppy M, Moreira TS, Takakura AC, et al
    Role of the locus coeruleus catecholaminergic neurons in the chemosensory control of breathing in a Parkinson's disease model.
    Exp Neurol. 2017;293:172-180.
    PubMed     Text format     Abstract available


    March 2017
  37. BIMPISIDIS Z, M Oberg C, Maslava N, Cenci MA, et al
    Differential effects of gaseous versus injectable anesthetics on changes in regional cerebral blood flow and metabolism induced by l-DOPA in a rat model of Parkinson's disease.
    Exp Neurol. 2017 Mar 8. pii: S0014-4886(17)30066.
    PubMed     Text format     Abstract available


    February 2017
  38. MONNOT C, Zhang X, Nikkhou-Aski S, Damberg P, et al
    Asymmetric dopaminergic degeneration and levodopa alter functional corticostriatal connectivity bilaterally in experimental parkinsonism.
    Exp Neurol. 2017 Feb 18. pii: S0014-4886(17)30048.
    PubMed     Text format     Abstract available


    January 2017
  39. FRAU R, Savoia P, Fanni S, Fiorentini C, et al
    The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
    Exp Neurol. 2017;291:1-7.
    PubMed     Text format     Abstract available


  40. HAO F, Yang C, Chen SS, Wang YY, et al
    Long-Term Protective Effects of AAV9-Mesencephalic Astrocyte-Derived Neurotrophic Factor Gene Transfer in Parkinsonian Rats.
    Exp Neurol. 2017 Jan 25. pii: S0014-4886(17)30016.
    PubMed     Text format     Abstract available


  41. FJODOROVA M, Torres EM, Dunnett SB
    Transplantation site influences the phenotypic differentiation of dopamine neurons in ventral mesencephalic grafts in Parkinsonian rats.
    Exp Neurol. 2017 Jan 25. pii: S0014-4886(17)30019.
    PubMed     Text format     Abstract available


    December 2016
  42. BENTEA E, Van Liefferinge J, Verbruggen L, Martens K, et al
    Zonisamide attenuates lactacystin-induced parkinsonism in mice without affecting system xc.
    Exp Neurol. 2016 Dec 23. pii: S0014-4886(16)30418.
    PubMed     Text format     Abstract available


    October 2016
  43. BECK MH, Haumesser JK, Kuhn J, Altschuler J, et al
    Short- and long-term dopamine depletion causes enhanced beta oscillations in the cortico-basal ganglia loop of parkinsonian rats.
    Exp Neurol. 2016;286:124-136.
    PubMed     Text format     Abstract available


    September 2016
  44. MULAS G, Espa E, Fenu S, Spiga S, et al
    Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
    Exp Neurol. 2016 Sep 30. pii: S0014-4886(16)30299.
    PubMed     Text format     Abstract available


  45. WU Q, Yang X, Zhang Y, Zhang L, et al
    Chronic mild stress accelerates the progression of Parkinson's disease in A53T alpha-synuclein transgenic mice.
    Exp Neurol. 2016;285.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: